MARKETS
Analyst Actions

Needham Initiates Coverage On InflaRx with Buy Rating, Announces Price Target of $8

Sep 14, 2026 · 06:37 AM ET· updated 11h ago

Needham analyst Joseph Stringer initiates coverage on InflaRx (NASDAQ:IFRX) with a Buy rating and announces Price Target of $8.

Share
Why It Matters

An analyst firm just started watching InflaRx and thinks it looks good. They picked a price target of $8 to show where they think the stock could go.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.